Compare Amgen, Inc. (AMGN) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Gemini Space Station Inc — how do they compare? Amgen, Inc. trades at $415.99 (market cap $224.14B), while Gemini Space Station Inc trades at $4.1 (market cap $512.05M). The key difference: Amgen, Inc. is far larger — about 437.7× Gemini Space Station Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| AMGN | GEMI | |
|---|---|---|
Market Cap | $224.14B | $512.05M |
Sector | Health | Technology |
52-Week High | $417.20 | $32.52 |
52-Week Low | $271.18 | $3.90 |
Enterprise Value | $267.45B | $502.04M |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Gemini Space Station (GEMI) trades at $4.085, down 0.61% on the day, with technical indicators showing a bearish trend. The company reported significant losses with a net income margin of -278.9% in 2025 and has missed earnings expectations for three consecutive quarters. Recent developments include a $100 million investment from Winklevoss Capital and the launch of commission-free stock trading as part of its super app strategy.
Despite analyst consensus pointing to upside potential with a $6.33 price target, GEMI faces substantial execution risks amid ongoing securities lawsuits and persistent negative profitability. The stock presents high-risk speculative appeal for investors betting on the company's financial infrastructure transformation, but current fundamentals remain deeply concerning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
